These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

248 related articles for article (PubMed ID: 35151115)

  • 1. Impact of EGFR exon 19 deletion subtypes on clinical outcomes in EGFR-TKI-Treated advanced non-small-cell lung cancer.
    Huang LT; Zhang SL; Han CB; Ma JT
    Lung Cancer; 2022 Apr; 166():9-16. PubMed ID: 35151115
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Patients harboring uncommon EGFR exon 19 deletion-insertion mutations respond well to first-generation EGFR inhibitors and osimeritinib upon acquisition of T790M.
    Wang Y; Zheng R; Hu P; Zhang Z; Shen S; Li X
    BMC Cancer; 2021 Nov; 21(1):1215. PubMed ID: 34774017
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Comparison of clinical outcomes of patients with non-small cell lung cancer harboring different types of epidermal growth factor receptor sensitive mutations after first-line EGFR-TKI treatment].
    Liu JJ; Zhang S; Wu CJ; Ma LX; Liu Y; Li H; Cui HX; Cheng Y
    Zhonghua Zhong Liu Za Zhi; 2016 Mar; 38(3):211-7. PubMed ID: 26988828
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Impact of Exon 19 Deletion Subtypes in EGFR-Mutant Metastatic Non-Small-Cell Lung Cancer Treated With First-Line Tyrosine Kinase Inhibitors.
    Rossi S; Toschi L; Finocchiaro G; Di Noia V; Bonomi M; Cerchiaro E; Ceresoli GL; Beretta GD; D'Argento E; Santoro A
    Clin Lung Cancer; 2019 Mar; 20(2):82-87. PubMed ID: 30473385
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinical impact of uncommon epidermal growth factor receptor exon 19 insertion-deletion variants on epidermal growth factor receptor-tyrosine kinase inhibitor efficacy in non-small-cell lung cancer.
    Peng X; Long X; Liu L; Zeng L; Yang H; Jiang W; Liao D; Li K; Wang J; Lizaso A; Mao X; Xu Q; Mansfield AS; Yang N; Zhang Y
    Eur J Cancer; 2020 Dec; 141():199-208. PubMed ID: 33171317
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Different treatment efficacies and T790M acquisition of EGFR-TKIs on NSCLC patients with variable Del-19 subtypes of EGFR.
    Wu SG; Gow CH; Chen YL; Liu YN; Tsai MF; Shih JY
    Int J Cancer; 2023 Jul; 153(2):352-363. PubMed ID: 36912241
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Uncommon EGFR mutations associate with lower incidence of T790M mutation after EGFR-TKI treatment in patients with advanced NSCLC.
    Yang S; Mao S; Li X; Zhao C; Liu Q; Yu X; Wang Y; Liu Y; Pan Y; Wang C; Gao G; Li W; Xiong A; Chen B; Sun H; He Y; Wu F; Chen X; Su C; Ren S; Zhou C
    Lung Cancer; 2020 Jan; 139():133-139. PubMed ID: 31786475
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clinical outcomes of advanced NSCLC patients with different EGFR exon 19 deletion subtypes treated with first-line tyrosine kinase inhibitors: A single-center ambispective cohort study.
    Gu Y; Yu J; Hu H; Zhang H; Cao B; Liang L
    Thorac Cancer; 2023 Nov; 14(31):3147-3160. PubMed ID: 37704565
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Different efficacy of EGFR tyrosine kinase inhibitors and prognosis in patients with subtypes of EGFR-mutated advanced non-small cell lung cancer: a meta-analysis.
    Wang H; Huang J; Yu X; Han S; Yan X; Sun S; Zhu X
    J Cancer Res Clin Oncol; 2014 Nov; 140(11):1901-9. PubMed ID: 24908327
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Possible differential EGFR-TKI efficacy among exon 19 deletional locations in EGFR-mutant non-small cell lung cancer.
    Kaneda T; Hata A; Tomioka H; Tanaka K; Kaji R; Fujita S; Tomii K; Katakami N
    Lung Cancer; 2014 Nov; 86(2):213-8. PubMed ID: 25304185
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficacy of Osimertinib in Patients with Lung Cancer Positive for Uncommon EGFR Exon 19 Deletion Mutations.
    Grant MJ; Aredo JV; Starrett JH; Stockhammer P; van Alderwerelt van Rosenburgh IK; Wurtz A; Piper-Valillo AJ; Piotrowska Z; Falcon C; Yu HA; Aggarwal C; Scholes D; Patil T; Nguyen C; Phadke M; Li FY; Neal J; Lemmon MA; Walther Z; Politi K; Goldberg SB
    Clin Cancer Res; 2023 Jun; 29(11):2123-2130. PubMed ID: 36913537
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The impact of
    Zhao C; Jiang T; Li J; Wang Y; Su C; Chen X; Ren S; Li X; Zhou C
    Transl Lung Cancer Res; 2020 Aug; 9(4):1149-1158. PubMed ID: 32953493
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Rational Application of First-Line EGFR-TKIs Combined with Antiangiogenic Inhibitors in Advanced EGFR-Mutant Non-Small-Cell Lung Cancer: A Systematic Review and Meta-Analysis.
    Ma JT; Guo YJ; Song J; Sun L; Zhang SL; Huang LT; Jing W; Zhao JZ; Han CB
    Biomed Res Int; 2021; 2021():8850256. PubMed ID: 33575349
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The efficacy of immune checkpoint inhibitors in advanced
    Hu J; Huang D; Wang Y; Li D; Yang X; Fu Y; Du N; Zhao Y; Li X; Ma J; Hu Y
    Front Immunol; 2022; 13():975246. PubMed ID: 36159795
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Heterogeneous Response to First-Generation Tyrosine Kinase Inhibitors in Non-Small-Cell Lung Cancers with Different EGFR Exon 19 Mutations.
    Xu H; Li W; Yang G; Li J; Yang L; Xu F; Yang Y; Ying J; Wang Y
    Target Oncol; 2020 Jun; 15(3):357-364. PubMed ID: 32418166
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The Association of Acquired T790M Mutation with Clinical Characteristics after Resistance to First-Line Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor in Lung Adenocarcinoma.
    Huang YH; Hsu KH; Tseng JS; Chen KC; Hsu CH; Su KY; Chen JJW; Chen HW; Yu SL; Yang TY; Chang GC
    Cancer Res Treat; 2018 Oct; 50(4):1294-1303. PubMed ID: 29334606
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Non-small cell lung cancer harbouring non-resistant uncommon EGFR mutations: Mutation patterns, effectiveness of epidermal growth factor receptor-tyrosine kinase inhibitors and prognostic factors.
    Chang LC; Lim CK; Chang LY; Chen KY; Shih JY; Yu CJ
    Eur J Cancer; 2019 Sep; 119():77-86. PubMed ID: 31425965
    [TBL] [Abstract][Full Text] [Related]  

  • 18.
    Zheng Q; Huang Y; Zhao H; Yang Y; Hong S; Hou X; Zhao Y; Ma Y; Zhou T; Zhang Y; Fang W; Zhang L
    Transl Lung Cancer Res; 2020 Jun; 9(3):471-483. PubMed ID: 32676311
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparison of clinical outcomes of patients with non-small-cell lung cancer harbouring epidermal growth factor receptor exon 19 or exon 21 mutations after tyrosine kinase inhibitors treatment: a meta-analysis.
    Sheng M; Wang F; Zhao Y; Li S; Wang X; Shou T; Luo Y; Tang W
    Eur J Clin Pharmacol; 2016 Jan; 72(1):1-11. PubMed ID: 26490356
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Impact of angiogenesis inhibitor eligibility on the prognosis of patients with non-small cell lung cancer harboring EGFR mutation.
    Kodama H; Kenmotsu H; Kawabata T; Notsu A; Yabe M; Nishioka N; Miyawaki E; Miyawaki T; Mamesaya N; Kobayashi H; Omori S; Wakuda K; Ono A; Naito T; Murakami H; Takahashi T
    Cancer Med; 2021 Nov; 10(21):7503-7513. PubMed ID: 34587359
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.